Details of the Drug Reposition

General Information of This Drug (ID: DM2YGNW)

Drug Name
Dactinomycin   DM2YGNW
Synonyms
Cosmegen; Dactinomicina; Dactinomycine; Dactinomycinum; Meractinomycin; ACT D; ACTINOMYCIN D AMP; Actactinomycin A IV; Actinomycin A IV; Actinomycin Aiv; Actinomycin I; Actinomycin IV; Actinomycin cl; Actinomycin x i; Antibiotic from Streptomyces parvullus; Chounghwamycin B; D Actinomycin; Dactinomycin D; Dactinomyein d; Dilactone actin omycindioic D acid; Dilactone actinomycin D acid; Dilactone actinomycindioic D acid; Lyovac cosmegen; Oncostatin K; Actinomycin 11 cosmegen; Actinomycin 7; Actinomycin C1; Actinomycin I1; Actinomycin X 1; Actinomycin X1; HBF 386; HBF 386 meractinomycin; X 97; AD (VAN); Actinomycin C (sub1); Actinomycin C(sub1); Actinomycin D (JP15); Actinomycin D, sodium deoxyribonucleic acid complex; Actinomycin I (sub1); Actinomycin I(sub 1); Actinomycin I(sub1); Actinomycin-IV; Actinomycindioic D acid, dilactone; Acto-D; COSMEGEN (TN); Dactinomicina [INN-Spanish]; Dactinomycin (USP); Dactinomycin [USAN:BAN]; Dactinomycine [INN-French]; Dactinomycinum [INN-Latin]; NP-005932; Actinomycin D deriv. of 3H-phenoxaocardazine; GNF-PF-1977; Actinomycin-[threo-val-pro-sar-meval]; Actinomyein-theo-val-pro-sar-meval; Actinomycin-(threo-val-pro-sar-meval); O)-(1-oxo-1,2-ethanediyl)]bis(N-methyl)L-valine; PXZ-THR-DVA-PRO-SAR-MVA-THR-DVA-PRO-SAR-MVA; DVA-DPR-SAR-MVA-(c1)DTH-PXZ-(c11)DTH-DVA-DPR-SAR-MVA; 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine; 4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-dicarboxamide
Therapeutic Class
Anticancer Agents
Drug Type
Small molecular drug
Structure
3D MOL is unavailable 2D MOL

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Wilms tumor DISB6T16 N.A. Approved [1]
Hamartoma DIS0I87H N.A. Approved [1]
Childhood kidney Wilms tumor DIS0NMK3 N.A. Approved [1]
Beckwith-Wiedemann syndrome DISH15GR N.A. Approved [1]
Adult kidney Wilms tumor DIS79FJF N.A. Approved [1]
Advanced cancer DISAT1Z9 2A00-2F9Z Approved [1]
Gestational trophoblastic neoplasia DIS4EJNA 2F33-2F76 Approved [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ewing sarcoma DISQYLV3 2B52 Discontinued in Phase 2 [2]
Rhabdomyosarcoma DISNR7MS 2B55 Discontinued in Phase 2 [3]
------------------------------------------------------------------------------------

References

1 Dactinomycin FDA Label
2 Hydroxychloroquine in Cardiovascular Disease in Patients With Chronic Kidney Disease: A Proof of Concept Study
3 Effect of Proton Pump Inhibitors on CF Pulmonary Exacerbations